Transverse Rectal Diameter: Predictor of Severity in Children With Chronic Functional Constipation
Neurogastroenterology & Motility · 2026
DOI: 10.1111/nmo.70253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurogastroenterology & Motility, 2026. Verfasst von F Proli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Constipation, Rectum. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
This study aims to evaluate transverse rectal diameter (TRD) as a predictor of clinical severity and response to conventional treatment in children with chronic functional constipation (CFC).
Methods
This longitudinal prospective study enrolled 105 children aged 4–17 years with CFC at Fondazione Policlinico A. Gemelli (Rome, Italy) from December 2021 to April 2025. We used the Constipation Scoring System (CSS), pelvic ultrasound (TRD, anterior wall thickness [WT], detrusor thickness [DT]), and follow‐up assessments at 2, 4, and 6 months. Patients without TRD or CSS improvement at 6 months underwent high‐resolution anorectal manometry (HR‐ARM). Statistical analysis included generalized linear mixed‐effects models.
Results
Children with megarectum (TRD ≥ 3 cm) showed higher CSS scores ( p = 0.002), TRD ( p = 0.001), WT ( p = 0.021), and longer constipation duration ( p = 0.005) compared to controls. TRD positively correlated with age ( p = 0.008) and CSS ( β = 1.41, p = 0.043). A significant reduction in TRD and WT was observed at 2 months posttreatment ( p < 0.001). Nine patients who failed to improve had type I dyssynergia confirmed on HR‐ARM. DT showed no significant correlation with clinical severity.
Conclusion
TRD measured by pelvic ultrasound is a reliable noninvasive marker for assessing severity and monitoring treatment response in pediatric CFC. Persistence of rectal dilatation may suggest underlying defecatory dyssynergia and guide further evaluation. Integration of TRD into routine practice could improve personalized, outpatient‐based care. Further multicentric studies are needed to validate TRD as a predictive biomarker in long‐term management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
- Università Cattolica del Sacro Cuore, Rome, Italy.
- UOSD Spina Bifida e Altre Branche Specialistiche, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
- Centre of Epidemiology, Biostatistics and Medical Information Technology, Faculty of Medicine and Surgery, Università Politecnica Delle Marche, Ancona, Italy.
- Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
ORCID-Profile: A Faragalli, F Viozzi, V Giorgio
Zitieren
APA
Proli, F., Margiotta, G., Stella, G., Faragalli, A., Gallo, F., Viozzi, F., Cherubino, A., Gasbarrini, A., Rendeli, C., & Giorgio, V. (2026). Transverse Rectal Diameter: Predictor of Severity in Children With Chronic Functional Constipation. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.70253
Vancouver
Proli F, Margiotta G, Stella G, Faragalli A, Gallo F, Viozzi F, et al. Transverse Rectal Diameter: Predictor of Severity in Children With Chronic Functional Constipation. Neurogastroenterology & Motility. 2026. doi:10.1111/nmo.70253
BibTeX
@article{Proli2026,
author = {Proli, F and Margiotta, G and Stella, G and Faragalli, A and Gallo, F and Viozzi, F and Cherubino, A and Gasbarrini, A and Rendeli, C and Giorgio, V},
title = {Transverse Rectal Diameter: Predictor of Severity in Children With Chronic Functional Constipation},
journal = {Neurogastroenterology & Motility},
year = {2026},
doi = {10.1111/nmo.70253}
}
EUVIMED